18 and older, any sex, with Human Immunodeficiency Virus. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Proportion of Time on Medication Among Pregnant WomenPrimary· 12 months
Specifically, every patient is given 30 days to pick up their medication, with a grace period of 5 days. If a patient picks up medication more than 35 days from their last pick-up, then they will be considered not on their medication from day 30 until the day of their next pick-up, at which time they will be assumed to be on medication again; this will be calculated over the course of the one-year follow-up.
Group
Value
95% CI
Standard of Care
0.67
± 0.26
Couples-based Services
0.66
± 0.27
Proportion of Days With Medication Among Male PartnerPrimary· 12 months
Proportion of days with medication (based on date of pick up and the number of pills provided by the pharmacy) among male partners
Group
Value
95% CI
Standard of Care
0.47
± 0.31
Couples-based Services
0.55
± 0.29
Sponsor's own description
The purpose of this R01 proposal is to evaluate the clinical impact, hypothesized mechanisms of behavior change, and cost-effectiveness of a partners-focused integrated elimination of mother-to-child transmission of HIV (EMTCT) package comprised of: 1) antenatal care-based couples HIV testing, ART enrollment, and care for sero-concordant HIV+ expectant couples; (2) Couples-based treatment in the post-partum period; (3) Couple-based education and skills building; and (4) Treatment continuity with the support of expert-patient (peer) supporters from couples who have successfully navigated EMTCT. This innovative approach to scaling up EMTCT services, if proven feasible and effective, will be adopted in President's Emergency Plan for AIDS Relief (PEPFAR) programs to accelerate progress toward EMTCT and helping families with HIV infection live long, healthy lives.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
Other recruiting trials for Human Immunodeficiency Virus
Currently open trials in the same condition.
NCT07530198 — HIV Therapeutic DNA Vaccine (ICVAX) Phase I Clinical Trial in Hong Kong
· Phase 1
· recruiting
NCT06819176 — Lenacapavir Intensification to Disrupt HIV Reservoirs in Virologically Suppressed People With HIV Receiving Antiretrovir
· Phase 1
· recruiting
NCT06408142 — Universal Test and Connect for HIV Service Delivery in South Africa
· recruiting
NCT07101458 — The Eswatini PRISM Study on Adolescents Living With HIV
· NA
· recruiting
NCT06554223 — The SUSTAIN 2 Study - SUStained HIV Treatment for Adherence After Interruption in Care
· NA
· recruiting
Other Vanderbilt University Medical Center trials
Trials by the same sponsor.
NCT07005037 — Swallowing Impairments in ICU Survivors and Community-Dwelling Adults
· not yet recruiting
NCT07527273 — Cognitive Enhancement in Recurrent Depression (The COG-D-R Study)
· NA
· not yet recruiting
NCT07295288 — Botox Injections in Non-Cranial Nerve VII Innervated Muscles for Facial Synkinesis
· Phase 4
· not yet recruiting
NCT07431541 — Topical Carboxytherapy Paste Following Microneedling
· Phase 1, PHASE2
· not yet recruiting
NCT07224711 — The Impact of Perioperative Lidocaine Infusions on Enhanced Recovery After Non-Cardiac Surgery
· Phase 4
· not yet recruiting
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Vanderbilt University Medical Center
Last refreshed: 21 August 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03149237.